Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Half of patients with active early rheumatoid arthritis achieved clinical remission

Clinical trial data demonstrate benefits of early treatment in patients with moderate to severe rheumatoid arthritis

Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that data from a multicenter, randomized, double-blind trial of ENBREL plus methotrexate showed that 50 percent of patients with active early rheumatoid arthritis achieved clinical remission at one year. In contrast, 28 percent of patients achieved clinical remission who were treated with methotrexate alone. The population under study had less than two years (median seven months) of moderately to severely active disease. Results from the COMET (COmbination of Methotrexate and ETanercept in Active Early Rheumatoid Arthritis) trial will be presented at the American College of Rheumatology (ACR) Scientific Meeting in Boston, Massachusetts.

COMET marks the first major rheumatoid arthritis (RA) clinical trial with ENBREL to use clinical remission as a primary endpoint, as measured by disease activity score (DAS28

"Clinical remission, as measured by DAS28, is an important goal in clinical practice, and is perhaps the most relevant to patients’ daily lives as they struggle with their symptoms,” said Paul Emery, professor of Rheumatology, University of Leeds, UK. "We hope that both patients and physicians are encouraged by these findings as they set a new standard for earlier treatment of RA."

The COMET study’s secondary endpoints included proportions of patients achieving ACR 20, ACR 50 and ACR 70 scores at week 52 following treatment with ENBREL plus methotrexate, compared to methotrexate alone. The study showed 48 percent of patients receiving ENBREL plus methotrexate achieved an ACR 70 score, versus 28 percent of the methotrexate-only group. Additionally, 71 percent of patients receiving combination therapy achieved an ACR 50 score, versus 49 percent of patients treated with methotrexate alone. The percentage of patients who achieve an ACR 50 or ACR 70 score represent those who achieve a 50 percent or 70 percent improvement in select RA symptoms, including joint swelling and tenderness, pain, level of disability, overall patient and physician disease assessment, and an objective marker of inflammation, such as erythrocyte sedimentation rate.

More than 2 million Americans suffer from RA, which can cause stiffness, swelling, and limitation in the motion and function of multiple joints. If RA is left untreated, patients can become disabled from irreversible joint damage caused by the disease, limiting their ability to function.

There were no differences in rates of serious infections or malignancies among patients in the ENBREL plus methotrexate group compared with the methotrexate-only group. No cases of TB or demyelinating disease were reported. No new safety signals were identified. In other RA clinical trials, the most common adverse events were injection site reaction, infection, and headache.


This study was designed to compare the clinical efficacy and safety of ENBREL and methotrexate combination therapy with methotrexate alone in patients with active early rheumatoid arthritis. Patients in this study had disease duration of ≤ 2 years, had not previously received methotrexate, and had active disease based on DAS28 (≥ 3.2) and elevation of erythrocyte sedimentation rate (≥ 28 mm/hr) or C-reactive protein (≥ 20 mg/L). Patients were randomized to receive either ENBREL plus methotrexate (n = 274) or methotrexate alone (n = 268). The primary endpoint was proportion of patients achieving DAS28 clinical remission (


ENBREL is a fully human soluble tumor necrosis factor (TNF) receptor. ENBREL was first approved in 1998 and has since been used in more than 460,000 patients worldwide across indications.

ENBREL indications in the U.S.:

ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with moderate to severe rheumatoid arthritis. ENBREL can be taken with methotrexate or used alone.

ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease modifying antirheumatic drugs.

ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with psoriatic arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.

ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

ENBREL is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

What important information do I need to know about taking prescription Enbrel® (etanercept)?

ENBREL is a type of protein called a tumor necrosis factor (TNF) blocker that blocks the action of a substance your body's immune system makes called TNF. People with an immune disease, such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis, have too much TNF in their bodies. ENBREL can reduce the amount of TNF in the body to normal levels, helping to treat your disease. But, in doing so, ENBREL can also lower the ability of your immune system to fight infections.

All medicines have side effects, including ENBREL. Possible side effects of ENBREL include:

Serious infections
-Many occurred in people prone to infection, such as those with advanced or poorly controlled diabetes
-Some serious infections have been fatal
-Rare cases of tuberculosis have occurred
What not to do
-Do not start ENBREL if you have an infection, such as an open sore or the flu, or are allergic to ENBREL or its components
What to do
-Tell your doctor if you are prone to infection or have had hepatitis B
-Stop ENBREL if a serious infection occurs
-Contact your doctor if you have questions about ENBREL or develop an infection
-Tell your doctor if you have ever been treated for heart failure
Serious nervous system disorders, such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes

-Tell your doctor if you have ever had any of these disorders or if you develop them after starting ENBREL

Rare reports of serious blood disorders (some fatal)
-Contact your doctor immediately if you develop symptoms, such as persistent fever, bruising, bleeding, or paleness
In medical studies of all TNF blockers, including ENBREL, a higher rate of lymphoma (a type of cancer) was seen compared to the general population. The risk of lymphoma may be up to several-fold higher in rheumatoid arthritis and psoriasis patients

-The role of TNF blockers, including ENBREL, in the development of lymphoma is unknown

ENBREL can cause injection site reaction

In a medical study of patients with JRA, infection, headache, abdominal pain, vomiting, and nausea occurred more frequently than in adults
-The kinds of infections reported were generally mild and similar to those usually seen in children

-Other serious adverse reactions were reported rarely, including serious infection (2 percent) and depression/personality disorder (1 percent)

Sonia Fiorenza | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht Scientists develop tiny tooth-mounted sensors that can track what you eat
22.03.2018 | Tufts University

nachricht NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Researchers Discover New Anti-Cancer Protein

An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from the Biozentrum, University of Basel, report in “Nature” that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer.

The incidence of liver cancer, also known as hepatocellular carcinoma, is steadily increasing. In the last twenty years, the number of cases has almost doubled...

Im Focus: Researchers at Fraunhofer monitor re-entry of Chinese space station Tiangong-1

In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.

Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...

Im Focus: Alliance „OLED Licht Forum“ – Key partner for OLED lighting solutions

Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.

They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...

Im Focus: Mars' oceans formed early, possibly aided by massive volcanic eruptions

Oceans formed before Tharsis and evolved together, shaping climate history of Mars

A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...

Im Focus: Tiny implants for cells are functional in vivo

For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.

In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

Latest News

Modular safety concept increases flexibility in plant conversion

22.03.2018 | Trade Fair News

New interactive map shows climate change everywhere in world

22.03.2018 | Earth Sciences

New technologies and computing power to help strengthen population data

22.03.2018 | Earth Sciences

Science & Research
Overview of more VideoLinks >>>